Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01659658
Registration number
NCT01659658
Ethics application status
Date submitted
2/08/2012
Date registered
8/08/2012
Date last updated
25/04/2024
Titles & IDs
Public title
Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
Query!
Scientific title
A Phase 3, Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physicians Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
Query!
Secondary ID [1]
0
0
2011-005468-10
Query!
Secondary ID [2]
0
0
C16011
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Relapsed or Refractory Systemic Light Chain Amyloidosis
0
0
Query!
Condition category
Condition code
Metabolic and Endocrine
0
0
0
0
Query!
Metabolic disorders
Query!
Metabolic and Endocrine
0
0
0
0
Query!
Other metabolic disorders
Query!
Human Genetics and Inherited Disorders
0
0
0
0
Query!
Other human genetics and inherited disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - IXAZOMIB
Treatment: Drugs - Dexamethasone
Treatment: Drugs - Melphalan
Treatment: Drugs - Cyclophosphamide
Treatment: Drugs - Thalidomide
Treatment: Drugs - Lenalidomide
Experimental: Arm A: Ixazomib + Dexamethasone - Ixazomib 4 mg, capsules, orally, once on Days 1, 8, and 15 and dexamethasone 20 mg, orally, once weekly on Days 1, 8, 15, and 22 of each 28-day cycle for up to a maximum of 95.2 months. Dexamethasone was increased up to 40 mg/day after 4 weeks, if tolerated.
Active Comparator: Arm B: Dexamethasone + Melphalan - Participants received dexamethasone 20 mg, orally, and melphalan 0.22 mg/kg, orally once on Days 1 through 4 of each 28-day cycle, for up to a maximum of 72.4 months.
Active Comparator: Arm B: Dexamethasone + Cyclophosphamide - Participants received dexamethasone 20 mg, orally, once weekly on Days 1, 8, 15, and 22, and cyclophosphamide 500 mg, orally, on Days 1, 8 and 15 of each 28-day cycle for up to a maximum of 72.4 months.
Active Comparator: Arm B: Dexamethasone + Thalidomide - Participants received dexamethasone 20 mg, orally, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle, and thalidomide daily at a starting dose of 50 mg and increased, as tolerated, to a maximum of 200 mg, orally for up to a maximum of 72.4 months.
Active Comparator: Arm B: Dexamethasone + Lenalidomide - Participants received dexamethasone 20 mg, orally, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle and lenalidomide 15 mg, orally, once on Days 1 through 21 every 28 days for up to a maximum of 72.4 months.
Treatment: Drugs: IXAZOMIB
IXAZOMIB capsules
Treatment: Drugs: Dexamethasone
Dexamethasone tablets
Treatment: Drugs: Melphalan
Melphalan tablets
Treatment: Drugs: Cyclophosphamide
Cyclophosphamide tablets
Treatment: Drugs: Thalidomide
Thalidomide capsules
Treatment: Drugs: Lenalidomide
Lenalidomide capsules
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants With Overall Hematologic Response
Query!
Assessment method [1]
0
0
Overall hematologic response was defined as the percentage of participants with complete response (CR), very good partial response (VGPR) and partial response (PR) based on central laboratory results and the 2010 International Society of Amyloidosis (ISA) Consensus Criteria as assessed by an adjudication committee. CR: Complete disappearance of M-protein from serum and urine on immunofixation, and normalization of free light chain (FLC) ratio. VGPR: differential free light chain (difference between involved and uninvolved FLC levels; dFLC) < 40 mg/L. PR: =50% reduction in dFLC. Percentages were rounded off to the nearest decimal.
Query!
Timepoint [1]
0
0
From first dose of study drug until discontinuation of study drug due to disease progression or unacceptable toxicity, or death whichever occurs first (up to 115 months)
Query!
Primary outcome [2]
0
0
2-Year Vital Organ (Heart or Kidney) Deterioration and Mortality Rate
Query!
Assessment method [2]
0
0
Cardiac (Heart) deterioration was defined as the need for hospitalization for heart failure. Kidney deterioration was defined as progression to end-stage renal disease (ESRD) with the need for maintenance dialysis or renal transplantation. Vital organ deterioration was evaluated by an adjudication committee. Percentages were rounded off to the nearest decimal. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure.
Query!
Timepoint [2]
0
0
Up to 2 years
Query!
Secondary outcome [1]
0
0
Percentage of Participants With Complete Hematologic Response
Query!
Assessment method [1]
0
0
Complete hematologic response was defined as the percentage of participants with CR based on central laboratory results and the 2010 ISA Consensus Criteria as assessed by the investigator. CR: Complete disappearance of M-protein from serum and urine on immunofixation, and normalization of FLC ratio. Percentages were rounded off to the nearest decimal. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure.
Query!
Timepoint [1]
0
0
From first dose of study drug until discontinuation of study drug due to disease progression or unacceptable toxicity, or death whichever occurs first (up to 115 months)
Query!
Secondary outcome [2]
0
0
Overall Survival
Query!
Assessment method [2]
0
0
Overall survival was defined as the time from the date of randomization to the date of death. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure.
Query!
Timepoint [2]
0
0
From first dose of study drug until discontinuation of study drug due to disease progression or unacceptable toxicity, or death whichever occurs first (up to 115 months)
Query!
Secondary outcome [3]
0
0
Progression Free Survival (PFS)
Query!
Assessment method [3]
0
0
PFS was defined as the time from the date of randomization to the date of first documentation of hematologic disease progression, or organ (cardiac or renal) progression, or death due to any cause, whichever occurred first according to central laboratory results and ISA criteria as evaluated by the investigator. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure.
Query!
Timepoint [3]
0
0
From first dose of study drug until discontinuation of study drug due to disease progression or unacceptable toxicity, or death whichever occurs first (up to 115 months)
Query!
Secondary outcome [4]
0
0
Hematologic Disease Progression Free Survival
Query!
Assessment method [4]
0
0
Hematologic disease PFS was defined as the time from the date of randomization to the date of first documentation of hematologic PD according to central laboratory results and ISA criteria as evaluated by an adjudication committee, or death due to any cause, whichever occurred first. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure.
Query!
Timepoint [4]
0
0
From first dose of study drug until discontinuation of study drug due to disease progression or unacceptable toxicity, or death whichever occurs first (up to 115 months)
Query!
Secondary outcome [5]
0
0
Time to Vital Organ (Heart or Kidney) Deterioration and Mortality Rate
Query!
Assessment method [5]
0
0
Time to vital organ deterioration or death was assessed by the investigator and defined as the time from randomization to vital organ (heart or kidney) deterioration or death, whichever occurs first. Cardiac deterioration is defined as the need for hospitalization for heart failure. Kidney deterioration is defined as progression to ESRD with the need for maintenance dialysis or renal transplantation. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure.
Query!
Timepoint [5]
0
0
From randomization to time of vital organ deterioration or death (up to 115 months)
Query!
Secondary outcome [6]
0
0
Percentage of Participants With Best Vital Organ (Cardiac and/or Kidney) Response
Query!
Assessment method [6]
0
0
Vital organ (heart and kidney) response rate was defined as the percentage of participants who achieved vital organ response according to central laboratory results and ISA criteria as evaluated by an adjudication committee. A vital organ response was defined as response of 1 or 2 of the involved vital organs with no change from Baseline in the rest of involved vital organs. Percentages were rounded off to the nearest decimal. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure.
Query!
Timepoint [6]
0
0
From first dose of study drug until discontinuation of study drug due to disease progression or unacceptable toxicity, or death whichever occurs first (up to 115 months)
Query!
Secondary outcome [7]
0
0
Vital Organ Progression Free Survival
Query!
Assessment method [7]
0
0
Vital organ PFS is defined as the time from the date of randomization to the date of first documentation of progression of vital organ (heart or kidney) according to central laboratory results and ISA criteria as evaluated by an adjudication committee, or death due to any cause, whichever occurs first. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure.
Query!
Timepoint [7]
0
0
From first dose of study drug until discontinuation of study drug due to disease progression or unacceptable toxicity, or death whichever occurs first (up to 115 months)
Query!
Secondary outcome [8]
0
0
Duration of Hematologic Response
Query!
Assessment method [8]
0
0
Duration of hematologic response (DOR) was defined as the time from the date of first documentation of a hematologic response to the date of first documented hematologic disease progression as determined by the investigator. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure.
Query!
Timepoint [8]
0
0
From time of first documented response to disease progression (up to 115 months)
Query!
Secondary outcome [9]
0
0
Number of Participants With Serious Adverse Events (SAEs)
Query!
Assessment method [9]
0
0
A SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of an existing hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly/birth defect or medically important event.
Query!
Timepoint [9]
0
0
From first dose of study drug through 30 days after administration of the last dose of study drug (up to 115 months)
Query!
Secondary outcome [10]
0
0
Time To Treatment Failure (TTF)
Query!
Assessment method [10]
0
0
TTF was defined as the time from randomization to the date of first documented treatment failure. Treatment failure was defined as: 1) death due to any cause; 2) hematologic progression or major organ progression according to central laboratory results and ISA criteria as evaluated by the investigator; 3) clinically morbid organ disease requiring additional therapy; or 4) withdrawn for any reason. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure.
Query!
Timepoint [10]
0
0
From first dose of study drug until discontinuation of study drug due to disease progression or unacceptable toxicity, or death whichever occurs first (up to 115 months)
Query!
Secondary outcome [11]
0
0
Time To Subsequent Anticancer Treatment
Query!
Assessment method [11]
0
0
Time to subsequent anticancer therapy was defined as the time from randomization to the first date of subsequent anticancer therapy. Participants without subsequent anticancer therapy were censored at the date of death or last known to be alive. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure.
Query!
Timepoint [11]
0
0
From first dose of study drug until subsequent anticancer treatment (up to 115 months)
Query!
Secondary outcome [12]
0
0
Change From Baseline in 36-item Short Form General Health Survey (SF-36) Mental Component Summary Score at Week 28 of the PFS Follow-up
Query!
Assessment method [12]
0
0
SF-36 Version 2 is a multipurpose, participant completed, short-form health survey with 36 questions that consists of an 8-scale profile of functional health and well-being scores as well as psychometrically-based physical and mental health summary measures. Physical component summary (PCS) is mostly contributed by physical function (PF), role physical (RP), bodily pain (BP), and general health (GH). Mental component summary (MCS) is mostly contributed by mental health (MH), role emotional (RE), social function (SF), and vitality (VT). Each component on the SF-36 item health survey is scored from 0 (best) to 100 (worst). Total score ranges from 0-100, where higher scores are associated with less disability and better quality of life. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure.
Query!
Timepoint [12]
0
0
Baseline, Week 28 of the PFS Follow-up
Query!
Secondary outcome [13]
0
0
Change From Baseline in SF-36 Physical Component Summary Score at Week 28 of the PFS Follow-up
Query!
Assessment method [13]
0
0
SF-36 Version 2 is a multipurpose, participant completed, short-form health survey with 36 questions that consists of an 8-scale profile of functional health and well-being scores as well as psychometrically-based physical and mental health summary measures. Physical component summary (PCS) is mostly contributed by physical function (PF), role physical (RP), bodily pain (BP), and general health (GH). Mental component summary (MCS) is mostly contributed by mental health (MH), role emotional (RE), social function (SF), and vitality (VT). Each component on the SF-36 item health survey is scored from 0 (best) to 100 (worst). Total score ranges from 0-100, where higher scores are associated with less disability and better quality of life. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure.
Query!
Timepoint [13]
0
0
Baseline, Week 28 of the PFS Follow-up
Query!
Secondary outcome [14]
0
0
Change From Baseline in Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) Score at Week 28 of the PFS Follow-up
Query!
Assessment method [14]
0
0
The FACT/GOG-Ntx is a participant completed questionnaire that comprises 11 individual items evaluating symptoms of neurotoxicity on a 5-point scale where: 0=not at all (best) to 4=very much for a total possible score of 0 to 44. Symptom scores are inverted so that higher scores of FACT/GOG-Ntx indicate higher quality of life or functioning. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure.
Query!
Timepoint [14]
0
0
Baseline, Week 28 of the PFS Follow-up
Query!
Secondary outcome [15]
0
0
Change From Baseline in Amyloidosis Symptom Scale Total Score at Week 28 of the PFS Follow-up
Query!
Assessment method [15]
0
0
The amyloidosis symptom scale questionnaire is a participant completed questionnaire that evaluates symptom severity of 3 symptoms: Swelling, Shortness of Breath and Dizziness, each rated on an 11-point scale where: 0=no symptoms to 10=very severe symptoms. Higher scores indicate worsening of symptoms. Total Score is the sum of all responses from the amyloidosis symptom scale ranging from 0 to 30. Higher scores represent higher levels of symptomatology or problems and a negative change from baseline indicates improvement. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure.
Query!
Timepoint [15]
0
0
Baseline, Week 28 of the PFS Follow-up
Query!
Secondary outcome [16]
0
0
Number of Participants in Each Category of the EuroQol 5-Dimensional (EQ-5D) Questionnaire Score
Query!
Assessment method [16]
0
0
The European Quality of Life (EuroQOL) 5-Dimensional (EQ-5D) is a patient completed questionnaire consisting of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 3 possible choices: no problems to extreme problems. Higher scores=worsening of the quality of life. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure.
Query!
Timepoint [16]
0
0
At Week 28 of the OS follow-up
Query!
Secondary outcome [17]
0
0
EuroQol 5-Dimension 3-Level (EQ-5D-3L) Visual Analogue Scale Score
Query!
Assessment method [17]
0
0
The EQ visual analogue scale (VAS) records the participant's self-rated health on a 20 centimeter vertical VAS that ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). Baseline is defined as the value collected at the time closest to, but prior to, the start of study drug administration. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure.
Query!
Timepoint [17]
0
0
At Week 28 of the OS follow-up
Query!
Secondary outcome [18]
0
0
Plasma Concentration of Ixazomib
Query!
Assessment method [18]
0
0
As prespecified in the protocol, data for this outcome measure was planned to be collected for ixazomib arm group only.
Query!
Timepoint [18]
0
0
Cycle 1, Day 1: 1, 4 hours postdose, Day 14: 144 hours postdose; Cycle 2, Day 1: predose, Day 14: 144 hours postdose; Cycles 3 to 10, Day 1: predose (cycle length=28 days)
Query!
Secondary outcome [19]
0
0
Number of Hospitalizations
Query!
Assessment method [19]
0
0
A hospitalization was defined as at least one overnight stay in an intensive care unit and/or non-intensive care unit. If a single hospitalization included both an intensive care unit stay and a non-intensive care unit stay, the hospitalization was counted only once (as an intensive care unit stay). The mean number of hospitalizations is reported in this outcome measure. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure.
Query!
Timepoint [19]
0
0
From first dose of study drug until discontinuation of study drug due to disease progression or unacceptable toxicity, or death whichever occurs first (up to 115 months)
Query!
Eligibility
Key inclusion criteria
1. Male or female participants 18 years or older.
2. Biopsy-proven diagnosis of primary systemic light chain amyloidosis (AL amyloidosis)
according to the following standard criteria:
1. Histochemical diagnosis of amyloidosis, as based on tissue specimens with Congo
red staining with exhibition of an apple-green birefringence
2. If clinical and laboratory parameters insufficient to establish AL amyloidosis or
in cases of doubt, amyloid typing may be necessary.
3. Measurable disease as defined by serum differential free light chain concentration
(dFLC, difference between amyloid forming [involved] and nonamyloid forming
[uninvolved] free light chain [FLC]) = 50 mg/L.
4. Objective, measurable major (cardiac or renal) organ amyloid involvement as defined as
follows (amyloid involvement of at least 1 required):
1. Cardiac involvement is defined as the presence of a mean left ventricular wall
thickness on echocardiogram greater than 12 mm in the absence of other potential
causes of left ventricular hypertrophy (controlled hypertension is allowed) with
a noncardiac biopsy showing amyloid, or a positive cardiac biopsy in the presence
of clinical or laboratory evidence of involvement. If there is isolated cardiac
involvement, then typing of amyloid deposits is recommended.
2. Renal involvement is defined as proteinuria (predominantly albumin) >0.5 g/day in
a 24-hour urine collection.
Note: Amyloid involvement of other organ systems is allowed, but not required.
5. Must be relapsed or refractory after 1 or 2 prior therapies. For this protocol,
relapsed is defined as progressive disease (PD) documented more than 60 days after
last dose; refractory is defined as documented absence of hematologic response or
hematologic progression on or within 60 days after last dose of prior therapy.
1. Participant must not have been previously treated with proteasome inhibitors.
(The sponsor reserves the right to open the study to proteasome inhibitor-exposed
participants in the future, at some time point after the first interim analysis
(IA). In that case, the participant may not be refractory to proteasome inhibitor
therapy.)
2. Given that the physician may select from an offered list of regimens to treat a
specific participant, the participant may be refractory to an agent/s listed
within the list of offered treatment choices
3. Must have recovered (ie, = Grade 1 toxicity or participant's baseline status)
from the reversible effects of prior therapy
4. If a participant has received a transplant as his/her first-line therapy, he/she
must be at least 3 months post transplantation and recovered from the side
effects of the stem cell transplant.
6. Must meet criteria for 1 of the following AL Amyloidosis Risk Stages (as defined by
N-terminal proBNP [NT-proBNP] cut-off of < 332 pg/mL and troponin T cut-off of 0.035
ng/mL as thresholds):
1. Stage 1: both NT-proBNP and troponin T under threshold
2. Stage 2: either NT-proBNP or troponin T (but not both) over threshold;
3. Stage 3: both NT-proBNP and troponin T over threshold (but NT-proBNP < 8000
pg/mL)
7. Eastern Cooperative Oncology Group (ECOG) Performance Status = 2.
8. Clinical laboratory values:
1. Absolute neutrophil count = 1000/µL
2. Platelet count = 75,000/µL
3. Total bilirubin = 1.5 upper limit of normal (ULN), except for participants with
Gilbert's syndrome as defined by > 80% unconjugated bilirubin and total bilirubin
= 6 mg/dL
4. Alkaline phosphatase = 5 x ULN
5. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =3 x ULN
6. Calculated creatinine clearance = 30 mL/min
9. Female participants who:
1. If they are of childbearing potential, agree to practice 2 effective methods of
contraception, at the same time, from the time of signing the informed consent
through 90 days after the last dose of study treatment, AND
2. Must also adhere to the guidelines of any treatment-specific pregnancy prevention
program, if applicable, OR
3. Agree to practice true abstinence when this is line with the preferred and usual
lifestyle of the participant. (Periodic abstinence [eg, calendar, ovulation,
symptothermal, post-ovulation methods] and withdrawal are not acceptable methods
of contraception.).
Male participants, even if surgically sterilized (ie, status post vasectomy), who:
1. Agree to practice effective barrier contraception during the entire study
treatment period and through 90 days after the last dose of study drug, AND
2. Must also adhere to the guidelines of any treatment-specific pregnancy prevention
program, if applicable, OR
3. Agree to practice true abstinence when this is line with the preferred and usual
lifestyle of the participant. (Periodic abstinence [eg, calendar, ovulation,
symptothermal, post-ovulation methods] and withdrawal are not acceptable methods
of contraception.)
10. Voluntary written consent must be given before performance of any study-related
procedure not part of standard medical care with the understanding that consent may be
withdrawn by the participant at any time without prejudice to future medical care.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Amyloidosis due to mutations of the transthyretin gene or presence of other non-AL
amyloidosis.
2. Female participants who are lactating, breast feeding, or pregnant.
3. Medically documented cardiac syncope, uncompensated New York Heart Association (NYHA)
Class 3 or 4 congestive heart failure, myocardial infarction within the previous 6
months, unstable angina pectoris, clinically significant repetitive ventricular
arrhythmias despite antiarrhythmic treatment, or severe orthostatic hypotension or
clinically important autonomic disease.
4. Clinically overt multiple myeloma, according to the International Myeloma Working
Group (IMWG) criteria with at least 1 of the following:
1. Bone lesions
2. Hypercalcemia, defined as a calcium of > 11 mg/dL
5. Inability to swallow oral medication, inability or unwillingness to comply with the
drug administration requirements, or gastrointestinal (GI) procedure that could
interfere with the oral absorption or tolerance of treatment.
6. Requirement for other concomitant chemotherapy, immunotherapy, radiotherapy, or any
ancillary therapy considered to be investigational or which would be considered as a
treatment of AL amyloidosis. However, participants may be on chronic steroids (maximum
dose 20 mg/day prednisone or equivalent) if they are being given for disorders other
than amyloidosis (eg, adrenal insufficiency, rheumatoid arthritis, etc.).
7. Comorbid systemic illnesses or other severe concurrent disease which, in the judgment
of the investigator, would make the participant inappropriate for entry into this
study or interfere significantly with the proper assessment of safety and toxicity of
the prescribed regimens.
8. Ongoing or active infection, known human immunodeficiency virus (HIV) positive, active
hepatitis B or C infection.
9. Psychiatric illness/social situations that would limit compliance with study
requirements.
10. Known allergy to boron, MLN9708, any of the study treatments, their analogues, or
excipients.
11. Systemic treatment with strong CYP3A inducers (rifampin, rifapentine, rifabutin,
carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort
within 14 days before the first dose of study treatment.
12. Diagnosed or treated for another malignancy within 3 years (or 5 years for
participants in France) before study enrollment or previously diagnosed with another
malignancy and have any evidence of residual disease. Participants with nonmelanoma
skin cancer or carcinoma in situ of any type are not excluded if they have undergone
complete resection.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
26/12/2012
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
11/07/2022
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
177
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Query!
Recruitment hospital [1]
0
0
Westmead Hospital - Westmead
Query!
Recruitment hospital [2]
0
0
Princess Alexandra Hospital - Woolloongabba
Query!
Recruitment hospital [3]
0
0
Box Hill Hospital - Box Hill
Query!
Recruitment hospital [4]
0
0
Sir Charles Gairdner Hospital - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
214 - Westmead
Query!
Recruitment postcode(s) [2]
0
0
4102 - Woolloongabba
Query!
Recruitment postcode(s) [3]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [4]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Illinois
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Indiana
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Massachusetts
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Michigan
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Minnesota
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Missouri
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
New York
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Ohio
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Tennessee
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Texas
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Wisconsin
Query!
Country [13]
0
0
Brazil
Query!
State/province [13]
0
0
Santa Catarina
Query!
Country [14]
0
0
Brazil
Query!
State/province [14]
0
0
Rio de Janeiro
Query!
Country [15]
0
0
Brazil
Query!
State/province [15]
0
0
Sao Paulo
Query!
Country [16]
0
0
Canada
Query!
State/province [16]
0
0
Alberta
Query!
Country [17]
0
0
Canada
Query!
State/province [17]
0
0
British Columbia
Query!
Country [18]
0
0
Canada
Query!
State/province [18]
0
0
Ontario
Query!
Country [19]
0
0
Czechia
Query!
State/province [19]
0
0
Moravskoslezsk Kraj
Query!
Country [20]
0
0
Czechia
Query!
State/province [20]
0
0
Praha, Hlavni Mesto
Query!
Country [21]
0
0
Denmark
Query!
State/province [21]
0
0
Aahus
Query!
Country [22]
0
0
Denmark
Query!
State/province [22]
0
0
Copenhagen
Query!
Country [23]
0
0
France
Query!
State/province [23]
0
0
Loire-Atlantique
Query!
Country [24]
0
0
France
Query!
State/province [24]
0
0
Lille
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Limoges
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Paris
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Toulouse
Query!
Country [28]
0
0
Germany
Query!
State/province [28]
0
0
Berlin
Query!
Country [29]
0
0
Germany
Query!
State/province [29]
0
0
Hamburg
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Heidelberg
Query!
Country [31]
0
0
Greece
Query!
State/province [31]
0
0
Achaia
Query!
Country [32]
0
0
Greece
Query!
State/province [32]
0
0
Athens
Query!
Country [33]
0
0
Israel
Query!
State/province [33]
0
0
Haifa
Query!
Country [34]
0
0
Israel
Query!
State/province [34]
0
0
Jerusalem
Query!
Country [35]
0
0
Israel
Query!
State/province [35]
0
0
Kfar Saba
Query!
Country [36]
0
0
Israel
Query!
State/province [36]
0
0
Petach Tikva
Query!
Country [37]
0
0
Israel
Query!
State/province [37]
0
0
Ramat-Gan
Query!
Country [38]
0
0
Italy
Query!
State/province [38]
0
0
Bologna
Query!
Country [39]
0
0
Italy
Query!
State/province [39]
0
0
Pavia
Query!
Country [40]
0
0
Korea, Republic of
Query!
State/province [40]
0
0
Incheon
Query!
Country [41]
0
0
Korea, Republic of
Query!
State/province [41]
0
0
Seoul
Query!
Country [42]
0
0
Netherlands
Query!
State/province [42]
0
0
Noord-Holland
Query!
Country [43]
0
0
Netherlands
Query!
State/province [43]
0
0
AZ Maastricht
Query!
Country [44]
0
0
Netherlands
Query!
State/province [44]
0
0
Utrecht
Query!
Country [45]
0
0
Spain
Query!
State/province [45]
0
0
Navarra
Query!
Country [46]
0
0
Spain
Query!
State/province [46]
0
0
Barcelona
Query!
Country [47]
0
0
Spain
Query!
State/province [47]
0
0
Madrid
Query!
Country [48]
0
0
Spain
Query!
State/province [48]
0
0
Majadahonda
Query!
Country [49]
0
0
Spain
Query!
State/province [49]
0
0
Salamanca
Query!
Country [50]
0
0
United Kingdom
Query!
State/province [50]
0
0
Birmingham
Query!
Country [51]
0
0
United Kingdom
Query!
State/province [51]
0
0
London
Query!
Country [52]
0
0
United Kingdom
Query!
State/province [52]
0
0
Manchester
Query!
Country [53]
0
0
United Kingdom
Query!
State/province [53]
0
0
Oxford
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Millennium Pharmaceuticals, Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to provide continued access of ixazomib and/or other study
medications and to continue collecting relevant safety data to monitor participant's safety,
determine whether dexamethasone plus IXAZOMIB improves hematologic response, 2-year vital
organ (that is, heart or kidney) deterioration and mortality rate versus a physician's choice
of a chemotherapy regimen in participants diagnosed with relapsed or refractory systemic
light chain (AL) amyloidosis.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01659658
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Medical Director
Query!
Address
0
0
Takeda
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01659658
Download to PDF